Clinical Trial Update: Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating sirolimus for injection (albumin-bound) in combination with octreotide long-acting injection in patients with metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• Octreotide Long-acting Injection (octreotide)
• Sirolimus for Injection (Albumin Bound) (sirolimus)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 2, Phase 3 | Status: RECRUITING